Page 5 - Absci News Today

Absci (NASDAQ:ABSI – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Tuesday, Zacks.com reports. According to Zacks, “Absci Corporation is the AI-powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. The company’s Creation(TM) Platform involved in […]

Absci (NASDAQ:ABSI – Get Rating) is one of 39 publicly-traded companies in the “Commercial physical research” industry, but how does it compare to its competitors? We will compare Absci to related companies based on the strength of its earnings, institutional ownership, risk, analyst recommendations, valuation, dividends and profitability. Profitability This table compares Absci and its […]

Absci (NASDAQ:ABSI – Get Rating) is one of 39 public companies in the “Commercial physical research” industry, but how does it compare to its competitors? We will compare Absci to similar businesses based on the strength of its profitability, risk, analyst recommendations, earnings, institutional ownership, valuation and dividends. Earnings & Valuation This table compares Absci […]

Zacks Investment Research downgraded shares of Absci (NASDAQ:ABSI – Get Rating) from a hold rating to a sell rating in a research report report published on Wednesday, Zacks.com reports. According to Zacks, “Absci Corporation is the AI-powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. The company’s Creation(TM) Platform […]

Absci Co. (NASDAQ:ABSI – Get Rating) was the target of a significant growth in short interest in the month of March. As of March 31st, there was short interest totalling 5,890,000 shares, a growth of 35.4% from the March 15th total of 4,350,000 shares. Based on an average daily volume of 1,500,000 shares, the days-to-cover […]

Absci Corp (NASDAQ:ABSI – Get Rating)’s stock price was down 11.2% during trading on Monday . The stock traded as low as $7.30 and last traded at $7.41. Approximately 8,172 shares were traded during trading, a decline of 100% from the average daily volume of 1,677,830 shares. The stock had previously closed at $8.34. Several […]

VANCOUVER, Wash., March 21, 2022 -- Absci Corporation , the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins,... | March 21, 2022

By Colin Kellaher Shares of Absci Corp. surged more than 50% in premarket trading Friday after the drug and target discovery company said it formed a research collaboration potentially worth... | January 7, 2022

Absci Announces Research Collaboration with Merck Collaboration to leverage Abscis Deep Learning-Enabled Drug Creation™ and Bionic Protein™... | January 7, 2022

AbSci Announces Strategic Investment by Merck Global Health Innovation Fund News provided by Share this article Share this article VANCOUVER, Wash., Feb. 22, 2021 /PRNewswire/ -- AbSci, a pioneering synthetic biology company that unifies biologic drug discovery and development processes, today announced a strategic equity investment by Merck Global Health Innovation Fund (Merck GHI) and potential discovery collaborations with Merck Research Laboratories. AbSci founder and CEO Sean McClain said...